Indian, German firms to collaborate on immunoglobulin products: Indian Embassy
The Indian mission facilitated the exchange of a non-disclosure agreement (NDA) between Germany's Neovii Biotech GmbH and India's VINS Bioproducts Ltd. on the sidelines of the Indo-German Health Leadership Dialogue on October 13, says Embassy of India in Berlin
The Indian Embassy in Berlin has announced that an Indian company, VINS Bioproducts Ltd, will collaborate with a German firm, Neovii Biotech GmbH, to develop and commercialize immunoglobulin products. This includes a drug utilized in organ transplantation and treatments for specific blood disorders. The collaboration will involve technology transfer to India, allowing local manufacturing and production of these specialized biological products.
The non-disclosure agreement (NDA) was exchanged during the Indo-German Health Leadership Dialogue on October 13, 2026. This partnership aims to bolster India's domestic production capabilities for such essential medical products and decrease the nation's dependence on imports.
Written by urgent.news from The Hindu Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
